Press Release: Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 14-16 January 2014: CVMP opinions on veterinary medicinal products

In January 2014 the Committee adopted by consensus positive opinions for initial marketing authorisation applications for:

Fungitraxx (itraconazole), from Avimedical B.V., an antifungal product for treatment of aspergillosis and candidiasis in identified species of ornamental birds. The product has been classified as MUMS/limited markets; and

Equisolon (prednisolone), from LE VET B.V., an anti-inflammatory product for use in horses with recurrent airway obstruction in combination with environmental control. The product has been classified as MUMS/limited markets.